These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 26830054)

  • 21. False amoxicillin/clavulanic acid susceptibility in Bacteroides fragilis using gradient strip tests.
    Rentenaar RJ; Bovo-Heijmans B; Diggle J; Fluit AC; Wootton M
    Anaerobe; 2021 Jun; 69():102358. PubMed ID: 33741507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study of the in vitro activity of amoxicillin/clavulanic acid and other beta-lactam antibiotics against Escherichia coli isolated from urine specimens.
    Vanhoof R; Carpentier M; Delannoy P; Fagnart O; Lontie M; Mans I; Nyssen HJ; Van Nimmen L
    Acta Clin Belg; 2001; 56(1):32-7. PubMed ID: 11307481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimal co-amoxiclav ratios for inhibiting Escherichia coli strains with different susceptibilities to the compounds.
    Gracia M; Ponte C; Soriano F
    Int J Antimicrob Agents; 2005 Apr; 25(4):352-3. PubMed ID: 15784320
    [No Abstract]   [Full Text] [Related]  

  • 24. Assessment of the Phoenix™ automated system and EUCAST breakpoints for antimicrobial susceptibility testing against isolates expressing clinically relevant resistance mechanisms.
    Giani T; Morosini MI; D'Andrea MM; García-Castillo M; Rossolini GM; Cantón R
    Clin Microbiol Infect; 2012 Nov; 18(11):E452-8. PubMed ID: 22909279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical breakpoint changes and their impact on surveillance of antimicrobial resistance in Escherichia coli causing bacteraemia.
    van der Bij AK; van Dijk K; Muilwijk J; Thijsen SF; Notermans DW; de Greeff S; van de Sande-Bruinsma N;
    Clin Microbiol Infect; 2012 Nov; 18(11):E466-72. PubMed ID: 22925456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Relationships between resistance to cefoxitin, ciprofloxacin and amoxicillin-clavulanic acid in Escherichia coli clinical isolates].
    Fernández-Cuenca F; Amblar G; Pascual A; Martínez-Martínez L
    Enferm Infecc Microbiol Clin; 2005 Oct; 23(8):510-1. PubMed ID: 16185572
    [No Abstract]   [Full Text] [Related]  

  • 27. Modified Antibiotic Adjuvant Ratios Can Slow and Steer the Evolution of Resistance: Co-amoxiclav as a Case Study.
    Allen RC; Brown SP
    mBio; 2019 Sep; 10(5):. PubMed ID: 31530673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral antibiotics for infections due to multidrug-resistant Gram-negative organisms.
    Glasser JS; Markelz AE; Zera WC; Beckius ML; Mende K; Murray CK
    Scand J Infect Dis; 2011 Aug; 43(8):649-51. PubMed ID: 21466257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of lower urinary tract infection caused by multidrug-resistant extended-spectrum-beta-lactamase-producing Escherichia coli with amoxicillin/clavulanate: case report and characterization of the isolate.
    Lagacé-Wiens PR; Nichol KA; Nicolle LE; DeCorby M; McCracken M; Mulvey MR; Zhanel GG
    J Antimicrob Chemother; 2006 Jun; 57(6):1262-3. PubMed ID: 16565157
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of cloned inhibitor-resistant TEM beta-lactamases on the susceptibility of Haemophilus influenzae to amoxicillin/clavulanate.
    Tristram SG; Burdach JG
    J Antimicrob Chemother; 2007 Nov; 60(5):1151-4. PubMed ID: 17827143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urine bactericidal activity against resistant Escherichia coli in an in vitro pharmacodynamic model simulating urine concentrations obtained after 2000/125 mg sustained-release co-amoxiclav and 400 mg norfloxacin administration.
    Alou L; Aguilar L; Sevillano D; Giménez MJ; Cafini F; Valero E; Relaño MT; Prieto J
    J Antimicrob Chemother; 2006 Apr; 57(4):714-9. PubMed ID: 16492718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The garden in our gut.
    Kmietowicz Z
    BMJ; 2015 Sep; 351():h5161. PubMed ID: 26424008
    [No Abstract]   [Full Text] [Related]  

  • 33. The resistance to betalactam antibiotics of lactose-positive and lactose-negative strains of Escherichia coli.
    Janicka G; Wojciechowska D; Hareńska K; Porada J; Kłyszejko C
    Acta Microbiol Pol; 1997; 46(4):399-403. PubMed ID: 9516987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ex vivo pharmacodynamics of amoxicillin-clavulanate against beta-lactamase-producing Escherichia coli in a yucatan miniature pig model that mimics human pharmacokinetics.
    Bronner S; Murbach V; Peter JD; Levêque D; Elkhaïli H; Salmon Y; Dhoyen N; Monteil H; Woodnutt G; Jehl F
    Antimicrob Agents Chemother; 2002 Dec; 46(12):3782-9. PubMed ID: 12435677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity in vitro of twelve antibiotics against clinical isolates of extended-spectrum beta-lactamase producing Escherichia coli.
    Sorlózano A; Gutiérrez J; Romero JM; de Dios Luna J; Damas M; Piédrola G
    J Basic Microbiol; 2007 Oct; 47(5):413-6. PubMed ID: 17910106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of co-amoxiclav acid against clinical isolates of Escherichia coli.
    Bertrand X; Talon D
    J Antimicrob Chemother; 2001 May; 47(5):725-6. PubMed ID: 11328800
    [No Abstract]   [Full Text] [Related]  

  • 37. [Strain of Escherichia coli resistant to broad-spectrum cephalosporin and amoxicillin/clavulanic acid].
    Martín-Pozo A; Alós JI
    Rev Esp Quimioter; 2012 Sep; 25(3):222-3. PubMed ID: 22987271
    [No Abstract]   [Full Text] [Related]  

  • 38. In vitro susceptibilities of Escherichia coli and Klebsiella spp. to ampicillin-sulbactam and amoxicillin-clavulanic acid.
    Kacmaz B; Sultan N
    Jpn J Infect Dis; 2007 Jul; 60(4):227-9. PubMed ID: 17642541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of Inhibitor-Resistant TEM β-Lactamases and Mechanisms of Fluoroquinolone Resistance in Escherichia coli Isolates.
    Ríos E; López MC; Rodríguez-Avial I; Pena I; Picazo JJ
    Microb Drug Resist; 2015 Oct; 21(5):512-5. PubMed ID: 25945693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro induction of resistance by tissue concentrations of azithromycin, clarithromycin, cefixime and amoxicillin/clavulanate in clinical isolates of Streptococcus pyogenes.
    De Vecchi E; Nicola L; Zucchetti E; Drago L
    J Chemother; 2006 Aug; 18(4):379-88. PubMed ID: 17024793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.